微创玻璃体切割术联合康柏西普玻璃体腔内注射治疗增生性糖尿病视网膜病变的临床疗效评估  

Clinical Efficacy Evaluation of Minimally Invasive Vitrectomy Combined with Conbercept Intravitreal Injection in the Treatment of Proliferative Diabetic Retinopathy

作　　者：伏海昕 朱振涛 王洁 敬志果 FU Haixin;ZHU Zhentao;WANG Jie;JING Zhiguo(Department of Ophthalmology,Huai'an Huai'an Hospital,Huai'an 223200,Jiangsu,China)

机构地区：[1]淮安市淮安医院眼科,江苏淮安223200

出　　处：《糖尿病新世界》2025年第1期166-169,共4页Diabetes New World

摘　　要：目的探讨微创玻璃体切割术联合康柏西普玻璃体腔内注射治疗增生性糖尿病视网膜病变的临床疗效。方法回顾性选取2021年8月—2024年5月淮安市淮安医院69例(76眼)增生性糖尿病视网膜病变患者的临床资料,按照不同的治疗方法分为两组,对照组(32例,36眼)接受微创玻璃体切割术联合雷珠单抗玻璃体腔内注射治疗;观察组(37例,40眼)接受微创玻璃体切割术联合康柏西普玻璃体腔内注射治疗。对比两组治疗前后的视力、眼压、黄斑中心凹厚度、生活质量及术后并发症发生率。结果治疗前,两组视力、眼压、黄斑中心凹厚度、生活质量比较,差异均无统计学意义(P均>0.05);治疗后,观察组视力、眼压、黄斑中心凹厚度及生活质量评分均优于对照组,差异均有统计学意义(P均<0.05)。两组并发症发生率比较,差异无统计学意义(P>0.05)。结论微创玻璃体切割术联合康柏西普显著改善视力、眼压和黄斑厚度,提升患者生活质量,具良好疗效与安全性。Objective To investigate the clinical efficacy of minimally invasive vitrectomy combined with intravitreal injection of conbercept in the treatment of proliferative diabetic retinopathy.Methods The clinical data of 69 patients(76 eyes)with proliferative diabetic retinopathy in Huai'an Huai'an Hospital from August 2021 to May 2024 were retrospectively selected and divided into two groups according to different treatment methods.The control group(32 cases,36 eyes)received minimally invasive vitrectomy combined with intravitreal injection of ranibizumab.The observation group(37 cases,40 eyes)received minimally invasive vitrectomy combined with intravitreal injection of conbercept.The visual acuity,intraocular pressure,macular foveal thickness,quality of life and incidence of postoperative complications were compared between the two groups before and after treatment.Results Before treatment,there were no significant differences in visual acuity,intraocular pressure,macular foveal thickness and quality of life between the two groups(all P>0.05).After treatment,the visual acuity,intraocular pressure,macular foveal thickness and quality of life scores of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion Minimally invasive vitrectomy combined with conbercept can significantly improve visual acuity,intraocular pressure and macular thickness,and improve the quality of life of patients,with good efficacy and safety.

关 键 词：增生性糖尿病视网膜病变 微创玻璃体切割术 雷珠单抗 康柏西普 临床疗效 

分 类 号：R779.6[医药卫生—眼科] R587.2[医药卫生—临床医学]